A Trial of Vigil for Participants With Ovarian Cancer
A phase 2 trial of Vigil in ovarian cancer, run by Gradalis, Inc., active and no longer recruiting.
Overview
A Trial of Vigil for Participants With Ovarian Cancer is a phase 2 interventional study registered as NCT02346747 by Gradalis, Inc., with 92 participants enrolled, started 2015-02 and due to reach its primary completion in 2028-12. Interventions recorded: Vigil.
Setting
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Phase
Phase 2
Sponsor
Gradalis, Inc.
Registry
Enrolled
92
Similar pages
not linked directly; found by shared links- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Shares Ovarian cancer and the tag pipeline.
- TrialA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialEffect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome
Shares Ovarian cancer and the tag pipeline.
- TrialTrial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Shares Ovarian cancer and the tag pipeline.
- TrialDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Shares Ovarian cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer and the tag pipeline.